25 results on '"Ona, Raquel"'
Search Results
2. Polatuzumab-R-CHP in Previously Untreated Diffuse Large B-Cell Lymphoma: A Retrospective Study
3. Clinical experience of bendamustine treatment for non-Hodgkin lymphoma and chronic lymphocytic leukemia in Spain
4. Relationship between deoxycytidine kinase ( DCK) genotypic variants and fludarabine toxicity in patients with follicular lymphoma
5. IBCL-265 Compassionate Use of Plitidepsin in Patients With Non-Hodgkin Lymphoma (NHL) and SARS-CoV-2 Infection
6. POSTER: IBCL-265 Compassionate Use of Plitidepsin in Patients With Non-Hodgkin Lymphoma (NHL) and SARS-CoV-2 Infection
7. Primary and Secondary Immunodeficiency Diseases in Oncohaematology: Warning Signs, Diagnosis, and Management
8. Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma
9. Germinal Predisposition in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction: Identification of Deleterious Variants in Microsatellite Instability Genes
10. Proof of Concept for Tipifarnib in Relapsed or Refractory Angioimmunoblastic T-Cell Lymphoma (AITL) and CXCL12+ Peripheral T-Cell Lymphoma (PTCL): Preliminary Results from an Open-Label, Phase 2 Study
11. Germline and Acquired Genetic Variants in Myelodysplastic Syndromes in Young Adults without a Preexisting Disorder or Organ Dysfunction
12. Extranodal Natural Killer/T-Cell Lymphoma Nasal Type in 87 Cases from Spain: Clinical Presentation, Treatment and Prognostic Factors. Study from the Geltamo Group
13. Geltamo-IPI Distinctly Identifies a Very High Risk Group in Difuse Large B-Cell Lymphoma (DLBCL) of Non B-Germinal-Center Origin Treated with Chemo-Immunotherapy
14. Evaluation of the MD Anderson Tumor Score and Their Tumor Related Prognostic Variables in the Rituximab Era
15. Validation of the NCCN-IPI for Diffuse Large B-Cell Lymphoma (DLBCL) in a Nation-Wide Spanish Series of 1885 Patients. the Geltamo-IPI Project
16. METODOLOGÍA DE INVENTARIACIÓN Y VALORACIÓN DE LOS PAISAJES VEGETALES.
17. Induction with Fludarabine, Cyclophosphamide and Rituximab Followed by Maintenance with Rituximab: Results of a Prospective Study in 75 Patients (LNHF-03).
18. Polymorphism -238 G/A in Promotor Region of Tumor Necrosis Factor alpha Gene Is a Risk Factor for Ischemic Cerebrovascular Disease in Spanish Population.
19. Factor V Leiden and Prothrombin G20210a Mutations in Young Adults with Ischemic Stroke.
20. Polymorphisms of Methylenetetrahydrofolate Reductase Gene and Risk of Ischemic Stroke in a Spanish Population.
21. A Phase 1/2 Study Of The Safety and Activity Of Escalating Doses Of Lenalidomide Plus Rituximab For Patients With Refractory Or Relapsed Chronic Lymphocytic Leukemia (LLC-Lenar-08)
22. The Pretreatment Absolute Lymphocyte Count (ALC), but Not the Absolute Monocyte Count (AMC) or ALC/AMC Ratio, Is an Independent Prognostic Factor in Aggressive Non-Hodgkin Lymphoma (aNHL)
23. Clinical and Biological Prognostic Factors Evaluation of Diffuse Large B-Cell Lymphoma Patients Relapsed or Refractory After Previous Line with Rituximab Plus Chemotherapy. Results of the Study PRO-R-IPI (NCT01369784),
24. Clinical Experience of Bendamustine Treatment for Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Spanish Registry.
25. Safety and Efficacy of Primary Prophylaxis with Voriconazole in Adult Patients with Acute Leukemia.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.